ACHN - Achillion Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.035
-0.105 (-3.34%)
As of 1:09PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close3.140
Open3.220
Bid3.030 x 800
Ask3.040 x 1800
Day's Range3.015 - 3.280
52 Week Range2.580 - 5.660
Volume565,300
Avg. Volume1,113,161
Market Cap419.862M
Beta0.32
PE Ratio (TTM)N/A
EPS (TTM)-0.623
Earnings DateAug 6, 2018 - Aug 10, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.58
Trade prices are not sourced from all markets
  • Achillion's 3rd Factor D Inhibitor Enters Clinical Studies
    Zacks5 days ago

    Achillion's 3rd Factor D Inhibitor Enters Clinical Studies

    Achillion (ACHN) commences a first-in-human phase I study on ACH-5548, a next-generation, oral small-molecule factor D inhibitor.

  • GlobeNewswire6 days ago

    Achillion Initiates Phase I First-in-Human Study of ACH-5548, a Third Oral Small Molecule Inhibitor of Complement Factor D

    Achillion Pharmaceuticals, Inc. (ACHN), a clinical-stage pharmaceutical company focused on developing small molecule inhibitors of factor D in the complement alternative pathway (AP), today announced that the Company had begun dosing healthy volunteer subjects in a first-in-human phase 1 trial of ACH-5548, an oral small-molecule complement factor D inhibitor. ACH-5548 is the third clinical compound discovered and developed by Achillion from its complement factor D platform.

  • ACCESSWIRE14 days ago

    Breakfast Technical Briefing on Amarin and Three Other Additional Biotech Stocks

    On Friday, June 29, 2018, US markets saw broad based gains with six out of nine sectors finishing the trading sessions in green. All you have to do is sign up today for this free limited time offer by clicking the link below.

  • Better Buy: Inovio Pharmaceuticals, Inc. vs. Achillion Pharmaceuticals, Inc.
    Motley Fool24 days ago

    Better Buy: Inovio Pharmaceuticals, Inc. vs. Achillion Pharmaceuticals, Inc.

    Which stock wins in a battle between these two clinical-stage biotechs?

  • GlobeNewswirelast month

    Achillion to Present at the 2018 JMP Securities Life Sciences Conference

    Achillion Pharmaceuticals, Inc. (ACHN) announced today that Joseph Truitt, President and Chief Executive Officer of Achillion, will present at the 2018 JMP Securities Life Sciences Conference on Thursday, June 21, 2018, at 9:00 a.m. ET at the St. Regis New York Hotel, in New York, NY. The live audio and subsequent archived webcasts of the Company's presentations will be accessible from the Company's investor relations website, http://ir.achillion.com. The audio recording will be archived for 30 days following the live presentation.

  • Achillion (ACHN) Down 6% Since Earnings Report: Can It Rebound?
    Zackslast month

    Achillion (ACHN) Down 6% Since Earnings Report: Can It Rebound?

    Achillion (ACHN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • GlobeNewswirelast month

    Investor Expectations to Drive Momentum within SK Telecom Co., Adaptimmune Therapeutics, Fiat Chrysler Automobiles N.V, Achillion Pharmaceuticals, Pzena Investment Management, and Sasol — Discovering Underlying Factors of Influence

    NEW YORK, June 01, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of SK ...

  • ACCESSWIRElast month

    Stock Performance Review on ACADIA Pharma and Three Other Biotech Stocks

    Losses were broad based as eight out of nine sectors finished the trading session in red. WallStEquities.com has initiated research reports on the following Biotechnology stocks: ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Achaogen Inc. (NASDAQ: AKAO), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), and Acorda Therapeutics Inc. (NASDAQ: ACOR).

  • Achillion Pharmaceuticals (ACHN): Moving Average Crossover Alert
    Zacks2 months ago

    Achillion Pharmaceuticals (ACHN): Moving Average Crossover Alert

    Achillion Pharmaceuticals, Inc. (ACHN) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

  • Benzinga2 months ago

    SMid-Cap Biotech: Barclays Downgrades Prothena, Upgrades Achillion

    Barclays revised its view of several smaller mid-cap biotech stocks after the first-quarter earnings season, issuing re-ratings Monday for Prothena Corporation PLC (NASDAQ: PRTA ) and Achillion Pharmaceuticals, ...

  • Benzinga2 months ago

    The Week Ahead In Biotech: PDUFA Dates, IPOs And More

    Some M&A activity , earnings news flow and clinical trial outcomes helped the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) preserve gains this week. As the earnings season winds down, here're ...

  • GlobeNewswire2 months ago

    Achillion Announces Upcoming Scientific Presentations at the 55th ERA-EDTA Congress

    Achillion Pharmaceuticals, Inc. (ACHN), a biopharmaceutical company focused on advancing oral small-molecule factor D inhibitors to modulate the complement alternative pathway for orphan diseases, today announced that two abstracts were accepted for presentation at the 55th European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress being hosted in Copenhagen, Denmark from May 24 – 27, 2018. Abstracts can be accessed on the ERA-EDTA website at http://www.era-edta2018.org/en-US/home.Reprints of the oral and poster presentations will be available following their presentation under the resources section of the Achillion website at http://www.achillion.com.

  • ACCESSWIRE2 months ago

    Wired News -Esperion Reported Positive Top-line Results from Late Stage Safety Study of its Cholestrol Drug - Bempedoic Acid

    LONDON, UK / ACCESSWIRE / May 4, 2018 / If you want access to our free research report on Esperion Therapeutics, Inc. (NASDAQ: ESPR) all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ESPR as the Company's latest news hit the wire. On May 2, 2018, the Company announced positive top-line results from the second pivotal, Phase-3 study (Study 1/1002-040) the long-term safety study, evaluating the safety, tolerability, and efficacy of bempedoic acid versus placebo in high-risk patients with atherosclerotic cardiovascular disease (ASCVD) who are inadequately controlled with current lipid-modifying therapies, including maximally tolerated statin therapy. Active-Investors.com is currently working on the research report for Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), which also belongs to the Healthcare sector as the Company Esperion Therapeutics.

  • GlobeNewswire2 months ago

    Achillion to Present at the Deutsche Bank 43rd Annual Health Care Conference

    Achillion Pharmaceuticals, Inc. (ACHN) announced today that Joseph Truitt, President and Chief Executive Officer of Achillion, will present a corporate overview at the Deutsche Bank 43rd Annual Health Care Conference on Tuesday, May 8, 2018, at 9:20 a.m. ET at the Intercontinental Boston Hotel, Boston, MA. The live audio and subsequent archived webcasts of the Company's presentations will be accessible from the Company's investor relations website, http://ir.achillion.com.

  • Achillion (ACHN) Posts Wider-Than-Expected Q1 Loss, Names CEO
    Zacks2 months ago

    Achillion (ACHN) Posts Wider-Than-Expected Q1 Loss, Names CEO

    Achillion Pharmaceuticals (ACHN) disappoints with wider-than-expected loss in the first quarter. Appoints Joseph Truitt as new CEO.

  • Associated Press2 months ago

    Achillion: 1Q Earnings Snapshot

    The New Haven, Connecticut-based company said it had a loss of 15 cents per share. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • GlobeNewswire2 months ago

    Achillion Reports First Quarter 2018 Financial Results and Management Transition

    Achillion Pharmaceuticals, Inc. (ACHN), a biopharmaceutical company focused on advancing oral small-molecule factor D inhibitors to modulate the complement alternative pathway, today reported financial results for the three months ended March 31, 2018. For the first quarter of 2018, the Company reported a net loss of $20.6 million or $0.15 per share, compared with a net loss of $20.2 million or $0.15 per share for the first quarter of 2017. Cash, cash equivalents, marketable securities and interest receivable as of March 31, 2018 were $308.4 million.

  • Are Options Traders Betting on a Big Move in Achillion Pharmaceuticals (ACHN) Stock?
    Zacks4 months ago

    Are Options Traders Betting on a Big Move in Achillion Pharmaceuticals (ACHN) Stock?

    Investors in Achillion Pharmaceuticals (ACHN) need to pay close attention to the stock based on moves in the options market lately.

  • Catalyst Pharmaceuticals Inc (CPRX) and Achillion Pharmaceuticals, Inc. (ACHN) Among Five Cheap Healthcare Stocks To Buy Now
    Insider Monkey4 months ago

    Catalyst Pharmaceuticals Inc (CPRX) and Achillion Pharmaceuticals, Inc. (ACHN) Among Five Cheap Healthcare Stocks To Buy Now

    There are plenty of opportunities to invest in healthcare stocks, as there are thousands of companies, ranging from big and well-established pharmaceuticals that also pay substantial dividends, to small, emerging companies without any products on the market or revenue, but backed by their research into novelty therapies for various illnesses. When looking for healthcare stocks […]

  • Alexion Pharmaceuticals: How Did Soliris Perform in 2017?
    Market Realist4 months ago

    Alexion Pharmaceuticals: How Did Soliris Perform in 2017?

    How's Alexion Pharmaceuticals Positioned after 4Q17?

  • Groupon Inc (GRPN), Globalstar, Inc. (GSAT) & More: Five Cheap Stocks to Buy Now
    Insider Monkey4 months ago

    Groupon Inc (GRPN), Globalstar, Inc. (GSAT) & More: Five Cheap Stocks to Buy Now

    Investing in cheap stocks can be risky and inexperienced investors are usually advised to stay clear of them, even though many new investors go straight to cheap stocks hoping to score big. Of course, in case of a successful investment, the returns can indeed be very big, given that cheap stocks are prone to bigger […]